Study shows DHPS enzyme controls macrophage maturation across multiple organs
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns…
Web-based cytometry atlas reveals immune signatures across pancreatic cancer treatments
Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of vaccines and…
Bacterial metabolite enhances immune checkpoint therapy against lung cancer
UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response…
Preclinical study reveals potential new treatment for severe liver fibrosis
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis – a dangerous, disease-induced build-up of…
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Longevity therapeutics market to double by 2033
Global longevity therapeutics market projected to hit US$43.72b by 2033, as supplements and antiaging solutions move from niche…
Artificial intelligence unlocks new frontiers in RNA drug design
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in…
Scientists create light-controlled versions of cholesterol
High levels of cholesterol are linked to heart disease, stroke, and many other health problems. However, this complex…
External signals control oncolytic bacteria for precise cancer therapy delivery
Engineered oncolytic bacteria have emerged as a promising therapeutic platform for precision cancer treatment, offering tumor-specific colonization, immune…
SN101 iPSC-derived therapy relieves chronic pain and preserves joints
SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach…
Study shines new light on how cancer avoids the mitotic stopwatch pathway
When cell division (mitosis) takes too long, it can be a sign that something is wrong with the…
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…